{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:55:12Z","timestamp":1794347712125,"version":"4.9.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high expression in most MM, with limited expression in other cell types, resulting in favorable on-target, off tumor toxicity. The response rate to autologous BCMA CAR-T therapy is high; however, it is not curative and is associated with risks of cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome. Outcomes in patients treated with BCMA CAR-T cells (CAR-Ts) may improve with allogeneic CAR T-cell therapy, which offer higher cell fitness and reduced time to treatment. However, to prevent the risk of graft-versus-host disease (GVHD), allogenic BCMA CAR-Ts require genetic deletion of the T-cell receptor (TCR), which has potential for unexpected functional or phenotype changes. Invariant natural killer T cells (iNKTs) have an invariant TCR that does not cause GVHD and, as a result, can be used in an allogeneic setting without the need for TCR gene editing. We demonstrate significant anti-myeloma activity of BCMA CAR-iNKTs in a xenograft mouse model of myeloma. We found that a long-acting interleukin-7 (IL-7), rhIL-7-hyFc, significantly prolonged survival and reduced tumor burden in BCMA CAR-iNKT\u2013treated mice in both primary and re-challenge settings. Furthermore, in CRS in\u00a0vitro assays, CAR-iNKTs induced less IL-6 than CAR-Ts, suggesting a reduced likelihood of CAR-iNKT therapy to induce CRS in patients. These data suggest that BCMA CAR-iNKTs are potentially a safer, effective alternative to BCMA CAR-Ts and that BCMA CAR-iNKT efficacy is further potentiated with rhIL-7-hyFc.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010032","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T19:14:07Z","timestamp":1688411647000},"page":"6009-6022","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc"],"prefix":"10.1182","volume":"7","author":[{"given":"Julie","family":"O\u2019Neal","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"},{"name":"2Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Cooper","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Ritchey","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Gladney","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Niswonger","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5129-8084","authenticated-orcid":false,"given":"L. Sof\u00eda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Street","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J.","family":"Haas","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Carter","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmeshwar N.","family":"Amayta","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"3Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-1226","authenticated-orcid":false,"given":"Byung Ha","family":"Lee","sequence":"additional","affiliation":[{"name":"4NeoImmuneTech, Inc, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[{"name":"4NeoImmuneTech, Inc, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-9159","authenticated-orcid":false,"given":"Melissa","family":"Berrien-Elliott","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"},{"name":"2Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"},{"name":"2Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-2887","authenticated-orcid":false,"given":"Todd A.","family":"Fehniger","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"},{"name":"2Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike P.","family":"Rettig","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"},{"name":"2Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO"},{"name":"2Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"issue":"5","key":"2023102313213340600_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2023102313213340600_bib2","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"13","key":"2023102313213340600_bib3","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T\u00a0cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2023102313213340600_bib4","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023102313213340600_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023102313213340600_bib6","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2023102313213340600_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2023102313213340600_bib8","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2012-01-404673","article-title":"Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival","volume":"120","author":"Rubio","year":"2012","journal-title":"Blood"},{"key":"2023102313213340600_bib9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant natural killer T Cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front Immunol"},{"issue":"11","key":"2023102313213340600_bib10","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"2023102313213340600_bib11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4049\/jimmunol.1800429","article-title":"IL-21 selectively protects CD62L(+) NKT cells and enhances their effector functions for adoptive immunotherapy","volume":"201","author":"Ngai","year":"2018","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"2023102313213340600_bib12","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1172\/JCI83476","article-title":"CD62L+ NKT cells have prolonged persistence and antitumor activity in\u00a0vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"23","key":"2023102313213340600_bib13","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in\u00a0vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2023102313213340600_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"2023102313213340600_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2023102313213340600_bib16","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.180.7.4415","article-title":"Innate-like effector differentiation of human invariant NKT cells driven by IL-7","volume":"180","author":"de Lalla","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"2023102313213340600_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cts.12800","article-title":"hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects","volume":"13","author":"Lee","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"23","key":"2023102313213340600_bib18","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1182\/bloodadvances.2021006591","article-title":"A\u00a0single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained functions and TCR diversity","volume":"6","author":"Kim","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2023102313213340600_bib19","doi-asserted-by":"crossref","first-page":"101097","DOI":"10.1016\/j.beha.2019.101097","article-title":"Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies","volume":"32","author":"Cooper","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2023102313213340600_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1073\/pnas.91.3.969","article-title":"Humanization of murine monoclonal antibodies through variable domain resurfacing","volume":"91","author":"Roguska","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2023102313213340600_bib21","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O\u2019Neal","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2023102313213340600_bib22","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.4049\/jimmunol.173.6.3620","article-title":"Kinetics of in\u00a0vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation","volume":"173","author":"Rettig","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2023102313213340600_bib23","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"issue":"19","key":"2023102313213340600_bib41","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1182\/blood-2011-03-340711","article-title":"Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome","volume":"119","author":"Astrakhan","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023102313213340600_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"8","key":"2023102313213340600_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023102313213340600_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B\u00a0cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur J Haematol"},{"issue":"8","key":"2023102313213340600_bib27","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2023102313213340600_bib28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023102313213340600_bib29","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"issue":"633","key":"2023102313213340600_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6","key":"2023102313213340600_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2023102313213340600_bib32","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"key":"2023102313213340600_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"2023102313213340600_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2023102313213340600_bib35","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"2023102313213340600_bib36","doi-asserted-by":"crossref","first-page":"897750","DOI":"10.3389\/fmed.2022.897750","article-title":"Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment","volume":"9","author":"Delfanti","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"21","key":"2023102313213340600_bib37","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","article-title":"Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023102313213340600_bib38","doi-asserted-by":"crossref","first-page":"567406","DOI":"10.3389\/fimmu.2020.567406","article-title":"IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA(-)CD62L(+)CD4(+) Invariant NKT Cells With Th-2 Biased Cytokine Production Profile","volume":"11","author":"Trujillo-Ocampo","year":"2020","journal-title":"Front Immunol"},{"key":"2023102313213340600_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2023102313213340600_bib40","author":"Ramos","year":"2022"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6009\/2085360\/blooda_adv-2023-010032-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/20\/6009\/2085360\/blooda_adv-2023-010032-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:22:02Z","timestamp":1698067322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6009\/496696\/Anti-myeloma-efficacy-of-CAR-iNKT-is-enhanced-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":41,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010032","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}